Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. While the majority of low-risk patients with localized prostate cancer have favourable outcomes, aggressive intermediate-risk and high-risk patients experience recurrence upon initial treatment and ultimately develop lethal metastatic disease. Hence, there remains a need to better our biological understanding of prostate cancer to improve patient care. Whole-genome sequencing revealed that primary prostate tumours are burdened by thousands of mutations with the majority residing in the noncoding space with unknown function. To address these gaps in our understanding, I investigated the impact of these noncoding mutations by focusing on their involvement in ge...
Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies are bas...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
We report a novel computational method, RegNetDriver, to identify regulatory drivers of tumorigenesi...
Cancer results from aberrations at the molecular level that enable biological hallmarks. These aberr...
Prostate Cancer is a lethal disease characterized as progressive and possessing distinct molecular h...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outco...
Prostate cancer is one of the most heritable human cancers. Genome-wide association studies have ide...
Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumo...
Whole genomes are being sequenced at an accelerated pace but research into cancer causing mutations ...
Many genetic variants affect disease risk by altering context-dependent gene regulation. Such varian...
Androgen receptor (AR) mediated signalling is critical to the growth at all stages of prostate cance...
Thousands of noncoding somatic single-nucleotide variants (SNVs) of unknown function are reported in...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Summary There is substantial heterogeneity among primary prostate cancers, evident in the spectrum o...
Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies are bas...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
We report a novel computational method, RegNetDriver, to identify regulatory drivers of tumorigenesi...
Cancer results from aberrations at the molecular level that enable biological hallmarks. These aberr...
Prostate Cancer is a lethal disease characterized as progressive and possessing distinct molecular h...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outco...
Prostate cancer is one of the most heritable human cancers. Genome-wide association studies have ide...
Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumo...
Whole genomes are being sequenced at an accelerated pace but research into cancer causing mutations ...
Many genetic variants affect disease risk by altering context-dependent gene regulation. Such varian...
Androgen receptor (AR) mediated signalling is critical to the growth at all stages of prostate cance...
Thousands of noncoding somatic single-nucleotide variants (SNVs) of unknown function are reported in...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
Summary There is substantial heterogeneity among primary prostate cancers, evident in the spectrum o...
Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies are bas...
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase I...
We report a novel computational method, RegNetDriver, to identify regulatory drivers of tumorigenesi...